Axsome Therapeutics, Inc. (AXSM) Stock

Axsome Therapeutics, Inc. (AXSM) is a Healthcare stock trading at $250.33 (as of 2026-06-18), with a market capitalization of $12.02B and a trailing P/E of -68.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders in the United States. Its pipeline includes product candidates in clinical-stage development for conditions such as major depressive disorder, Alzheimer’s disease agitation, migraine, narcolepsy, and fibromyalgia.

Valuation — source: SEC EDGAR (first-party)
Price	$250.33
Market Cap	$12.02B
P/E Ratio	-68.6
EV / EBITDA	-75.4
Price / Book	240.55
Price / Sales	18.54
DCF Value (model)	$-28.60
DCF Upside vs Price	-111.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$638.50M
Net Margin	-28.7%
Return on Equity	-345.0%
Debt / Equity	3.44
Current Ratio	1.39
Revenue Growth (YoY)	65.5%
EPS Growth (YoY)	-38.6%
FCF Growth (YoY)	-27.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	10.62 (safe)

Valuation vs Sector & Industry
Stock P/E	-68.6
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-427.3%
vs Industry	-497.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($760.66M)
Institutional Holders Tracked	10
Congressional Trades (recent)	1

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Herriot Tabuteau
Employees	712
Country	US
IPO Date	2015-11-19

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.